Aadi Bioscience to Announce First Quarter 2022 Financial Results on May 12, 2022

Rhea-AI Summary

Aadi Bioscience (Nasdaq: AADI) will report its Q1 2022 results on May 12, 2022, before the market opens. Following this, a conference call will be held at 8:30 am EDT to discuss the results and provide a corporate update. Aadi focuses on precision therapies for cancers related to mTOR pathway gene alterations. The company’s FYARRO™ has received FDA approval for treating a rare tumor and is now commercially available. Aadi is also advancing its clinical pipeline with the launch of the PRECISION 1 trial targeting specific solid tumors.

Positive

• FDA approval of FYARRO™ for treating malignant perivascular epithelioid cell tumor.
• Commercial launch of FYARRO in February 2022.
• Initiation of PRECISION 1, a Phase 2 trial for mTOR inhibitor-naïve solid tumors.

Negative

• None.

Company to hold conference call on May 12th at 8:30 am EDT

LOS ANGELES, April 28, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that it will report results for the first quarter 2022 before market open on Thursday, May 12, 2022. Aadi management will then host a conference call and webcast at 8:30 am EDT (5:30 am PDT) to discuss the results as well as provide a corporate update.

Individuals may join the webcast online by clicking here or may participate in the live call via telephone by dialing (877) 407-9716 (domestic) or (201) 493-6779 (international) and using conference ID 13729259. A replay of the call will also be available through Aadi’s website within the “Investors & News/Event Calendar” section.

About Aadi Bioscience

Aadi Bioscience, Inc. is a biopharmaceutical company focused on precision therapies for genetically-defined cancers. Aadi’s primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. In November 2021, Aadi received FDA approval for FYARRO™ for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa), and in February 2022 Aadi announced the commercial launch of FYARRO in this indication.

Based on data from Aadi’s AMPECT trial with FYARRO and following discussions with the FDA about other emerging data with FYARRO, Aadi has initiated PRECISION 1, a tumor-agnostic Phase 2 registrational trial in mTOR inhibitor-naïve solid tumors harboring TSC1 or TSC2 inactivating alterations. More information on Aadi’s development pipeline is available on the Aadi website at www.aadibio.com.

Contacts:

Investors

Irina Koffler
LifeSci Advisors LLC
ikoffler@lifesciadvisors.com 

FAQ

When will Aadi Bioscience report its Q1 2022 earnings?

Aadi Bioscience will report its Q1 2022 results on May 12, 2022.

What is the purpose of the Aadi Bioscience conference call?

The conference call will discuss the Q1 2022 results and provide a corporate update.

What is FYARRO™ and its significance for Aadi Bioscience?

FYARRO™ is a drug approved by the FDA for a specific type of cancer, marking a significant achievement for Aadi.

What is the PRECISION 1 trial initiated by Aadi Bioscience?

The PRECISION 1 trial is a Phase 2 registrational study targeting solid tumors with specific genetic alterations.